Cross-source evidence timeline
Metreleptin research timeline
Follow 43 selected, directly cited source records from October 30, 2013 through November 9, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT02262806↗
PeptideScanner retained ClinicalTrials.gov record NCT02262806 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05164341↗
PeptideScanner retained ClinicalTrials.gov record NCT05164341 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Literature metadata
Metreleptin treatment of non-HIV lipodystrophy syndromes.↗
PubMed lists PMID 34571177 in Presse medicale (Paris, France : 1983) as Journal Article, Review, with publication-date metadata of 2021-09-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 24, 2021 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT02262832↗
PeptideScanner retained ClinicalTrials.gov record NCT02262832 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Literature metadata
Case Report: Twenty years of metreleptin therapy in congenital generalized lipodystrophy type 1: the longest reported follow-up to date.↗
PubMed lists PMID 42222073 in Frontiers in endocrinology as Case Reports, Journal Article, with publication-date metadata of 2026-05-13 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: May 13, 2026 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT06305182↗
PeptideScanner retained ClinicalTrials.gov record NCT06305182 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT02325674↗
PeptideScanner retained ClinicalTrials.gov record NCT02325674 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT06679270↗
PeptideScanner retained ClinicalTrials.gov record NCT06679270 at 2026-11-16T17:35:38.955Z. Its registry update date was 2026-07-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Literature metadata
First metreleptin treatment for generalized lipodystrophy in Turkey.↗
PubMed lists PMID 27717125 in Diabetes, obesity & metabolism as Case Reports, Letter, with publication-date metadata of 2016-11-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 9, 2016 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT04026178↗
PeptideScanner retained ClinicalTrials.gov record NCT04026178 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-11-26, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Literature metadata
Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.↗
PubMed lists PMID 41080980 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-10-09 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 9, 2025 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Long-Term Clinical Experience With Metreleptin in a Brazilian Patient With Congenital Generalized Lipodystrophy Type 2.↗
PubMed lists PMID 40860570 in JCEM case reports as Case Reports, Journal Article, with publication-date metadata of 2025-08-22 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 22, 2025 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT06484868↗
PeptideScanner retained ClinicalTrials.gov record NCT06484868 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-07-03, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT05351164↗
PeptideScanner retained ClinicalTrials.gov record NCT05351164 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00085982↗
PeptideScanner retained ClinicalTrials.gov record NCT00085982 at 2026-11-16T17:35:38.955Z. Its registry update date was 2025-01-30, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026
Source year
2024
Literature metadata
New advances in the treatment of generalized lipodystrophy: role of metreleptin.↗
PubMed lists PMID 26396524 in Therapeutics and clinical risk management as Journal Article, Review, with publication-date metadata of 2015-09-16 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 16, 2015 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2023
Literature metadata
Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.↗
PubMed lists PMID 25070319 in The Journal of clinical endocrinology and metabolism as Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2014-07-29 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 29, 2014 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2022
Literature metadata
Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin.↗
PubMed lists PMID 30923630 in Clinical diabetes and endocrinology as Case Reports, Journal Article, with publication-date metadata of 2019-03-14 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 14, 2019 · day precisionAdded to PeptideScanner November 16, 2026
Source year
2021
Literature metadata
Metreleptin for the treatment of progressive encephalopathy with/without lipodystrophy (PELD) in a child with progressive myoclonic epilepsy: a case report.↗
PubMed lists PMID 33099310 in Italian journal of pediatrics as Case Reports, Journal Article, with publication-date metadata of 2020-10-24 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 24, 2020 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
W(h)ither metreleptin for lipodystrophy and the metabolic syndrome?↗
PubMed lists PMID 20350904 in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists as Editorial, Comment, with publication-date metadata of 2010 Mar-Apr (source-text precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: 2010 Mar-Apr · source-text precisionAdded to PeptideScanner November 16, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT02654977↗
PeptideScanner retained ClinicalTrials.gov record NCT02654977 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Literature metadata
Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report.↗
PubMed lists PMID 30745727 in Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology as Journal Article, with publication-date metadata of 2019-01-31 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 31, 2019 · day precisionAdded to PeptideScanner November 16, 2026Literature metadata
Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes.↗
PubMed lists PMID 31300002 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-07-12 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 12, 2019 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00657605↗
PeptideScanner retained ClinicalTrials.gov record NCT00657605 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00659828↗
PeptideScanner retained ClinicalTrials.gov record NCT00659828 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026
Source year
2019
Clinical trials
ClinicalTrials.gov record NCT01778556↗
PeptideScanner retained ClinicalTrials.gov record NCT01778556 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-11-13, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00461552↗
PeptideScanner retained ClinicalTrials.gov record NCT00461552 at 2026-11-16T17:35:38.955Z. Its registry update date was 2019-05-09, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026
Source year
2018
Literature metadata
Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.↗
PubMed lists PMID 26063386 in Expert opinion on biological therapy as Journal Article, Review, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: July 2015 · month precisionAdded to PeptideScanner November 16, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT00596934↗
PeptideScanner retained ClinicalTrials.gov record NCT00596934 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-11-24, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Literature metadata
USAN Council. List No.431. New names. Metreleptin.↗
PubMed lists PMID 11184472 in Clinical pharmacology and therapeutics as Journal Article, with publication-date metadata of 2000-10 (month precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 2000 · month precisionAdded to PeptideScanner November 16, 2026Literature metadata
Metreleptin (Myalept): a leptin analog for generalized lipodystrophy.↗
PubMed lists PMID 25581107 in The Medical letter on drugs and therapeutics as Journal Article, Review, with publication-date metadata of 2015-01-19 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 19, 2015 · day precisionAdded to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT01679197↗
PeptideScanner retained ClinicalTrials.gov record NCT01679197 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-14, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00140231↗
PeptideScanner retained ClinicalTrials.gov record NCT00140231 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-06-07, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00130117↗
PeptideScanner retained ClinicalTrials.gov record NCT00130117 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-05-17, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT01155180↗
PeptideScanner retained ClinicalTrials.gov record NCT01155180 at 2026-11-16T17:35:38.955Z. Its registry update date was 2017-04-07, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026
Source year
2016
Regulatory
Federal Register notice 2016-22935↗
The Federal Register published notice 2016-22935, attributed to FDA and its parent HHS department, on 2016-09-23. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MYALEPT,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.↗
Added to PeptideScanner November 17, 2026Clinical trials
ClinicalTrials.gov record NCT00025883↗
PeptideScanner retained ClinicalTrials.gov record NCT00025883 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-08-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT01511016↗
PeptideScanner retained ClinicalTrials.gov record NCT01511016 at 2026-11-16T17:35:38.955Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026
Source year
2015
Clinical trials
ClinicalTrials.gov record NCT00710814↗
PeptideScanner retained ClinicalTrials.gov record NCT00710814 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-11-16, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00673387↗
PeptideScanner retained ClinicalTrials.gov record NCT00673387 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-15, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026Clinical trials
ClinicalTrials.gov record NCT00392925↗
PeptideScanner retained ClinicalTrials.gov record NCT00392925 at 2026-11-16T17:35:38.955Z. Its registry update date was 2015-04-14, and PeptideScanner's reviewed identity mapping was metreleptin.↗
Added to PeptideScanner November 16, 2026
Source year
2014
Regulatory
Drugs@FDA application BLA125390↗
The official Drugs@FDA dataset lists original submission 1 for BLA 125390 with status AP dated 2014-02-24, and names metreleptin among the application record's active ingredients.↗
Added to PeptideScanner November 17, 2026
Source year
2013
Regulatory
Federal Register notice 2013-25588↗
The Federal Register published notice 2013-25588, attributed to FDA and its parent HHS department, on 2013-10-30. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Metreleptin.↗
Added to PeptideScanner November 17, 2026